12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Company News  |  Other News

Depomed neurology news

Depomed sued FDA in the U.S. District Court for the District of Columbia seeking to force the agency to grant Orphan Drug exclusivity for Gralise gabapentin to manage postherpetic neuralgia. In its complaint, Depomed claimed FDA violated the Orphan Drug Act by denying Gralise seven years of Orphan exclusivity...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >